title: Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma.
abstract: Small bowel adenocarcinomas (SBAs) are rarely seen tumors. Data regarding the use of chemotherapy together with bevacizumab in patients with advanced SBA are lacking. The aim of this study was the evaluation of treatment with bevacizumab in advanced SBA.
  
  
  
  Twenty-eight patients from 5 centers with a diagnosis of advanced SBA who received first-line treatments with modified FOLFOX6 (mFOLFOX6; oxaliplatin, leucovorin, and 5-fluorouracil) and FOLFIRI (leucovorin, 5-fluorouracil, and irinotecan) chemotherapy regimens were involved in the study. All patients were divided into 2 groups; those who received bevacizumab together with these chemotherapy regimens (Chemo+Bev group) and those who did not receive bevacizumab (Chemo group).
  
  
  
  The median progression-free survival (PFS) and overall survival (OS) times of all population were 8.7 months and 16.9 months, respectively. The overall response rate was 43.7% in the Chemo group and 58.3% in the Chemo+Bev group. The median PFSs in the Chemo and Chemo+Bev groups were found to be 7.7 months and 9.6 months, respectively, and the median OSs were 14.8 months and 18.5 months, respectively. There was not a significant difference between the groups in terms of overall response rate, PFS, and OS.
  
  
  
  Although there was no significant difference in any of the outcomes, use of bevacizumab together with chemotherapy is a more effective treatment approach compared with chemotherapy alone, and it does not cause an excess of significant toxicity.
authors.affiliation: Department of Medical Oncology, Dr Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey. Electronic address: dinceraydin79@yahoo.com.
authors.forename: Dincer
authors.initials: D
authors.lastname: Aydin
authors.affiliation: Department of Medical Oncology, Numune Education and Research Hospital, Ankara, Turkey.
authors.forename: Mehmet Ali
authors.initials: MA
authors.lastname: Sendur
authors.affiliation: Department of Medical Oncology, School of Medicine, Kocaeli University, Kocaeli, Turkey.
authors.forename: Umut
authors.initials: U
authors.lastname: Kefeli
authors.affiliation: Department of Medical Oncology, Haydarpasa Education and Research Hospital, Istanbul, Turkey.
authors.forename: Basak Bala
authors.initials: BB
authors.lastname: Ustaalioglu
authors.affiliation: Department of Medical Oncology, Haydarpasa Education and Research Hospital, Istanbul, Turkey.
authors.forename: Ozhan
authors.initials: O
authors.lastname: Aydin
authors.affiliation: Department of Medical Oncology, Dr Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.
authors.forename: Emre
authors.initials: E
authors.lastname: Yildirim
authors.affiliation: Department of Medical Oncology, Dr Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.
authors.forename: Deniz
authors.initials: D
authors.lastname: Isik
authors.affiliation: Department of Medical Oncology, Dr Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.
authors.forename: Melike
authors.initials: M
authors.lastname: Ozcelik
authors.affiliation: Department of Medical Oncology, Dr Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.
authors.forename: Heves
authors.initials: H
authors.lastname: Surmeli
authors.affiliation: Department of Medical Oncology, Dr Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.
authors.forename: Abdilkerim
authors.initials: A
authors.lastname: Oyman
authors.affiliation: Department of Medical Oncology, Dr Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.
authors.forename: Selver
authors.initials: S
authors.lastname: Isik
authors.affiliation: Department of Medical Oncology, Dr Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.
authors.forename: Nur
authors.initials: N
authors.lastname: Sener
authors.affiliation: Department of Medical Oncology, Dr Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.
authors.forename: Ozlem
authors.initials: O
authors.lastname: Ercelep
authors.affiliation: Department of Medical Oncology, Dr Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.
authors.forename: Hatice
authors.initials: H
authors.lastname: Odabas
authors.affiliation: Department of Medical Oncology, Dr Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Aliustaoglu
authors.affiliation: Department of Medical Oncology, Faculty of Medicine, Bezmialem University, Istanbul, Turkey.
authors.forename: Mahmut
authors.initials: M
authors.lastname: Gumus
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000068258:Bevacizumab / Q000008:administration & dosage*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy*; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D016019:Survival Analysis
chemical_list: D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin
keywords: Adenocarcinoma; Advanced; Bevacizumab; Bowel; Small